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Abstract 
 
This study aimed to investigate the role played by treatment supporters in promoting patients’ 
treatment outcomes in six TB clinics of Ekurhuleni Metropolitan Municipality, Gauteng. A 
descriptive research design was used to study TB patients who were registered in the clinics 
in April and May 2006. Interviews were conducted on 216 new adult patients six months after 
their registration at clinics, all 30 treatment supporters of those who had supporters and the 
staff responsible for TB at the six clinics at which the patients were registered.   
The patients were grouped into those who had supporters 53% (n=115) and those who did 
not 47% (n=101). Patients’ response rate was 97%. Treatment outcomes were compared 
between these two groups. 
Results showed that significantly more supported patients achieved successful outcomes 
than patients who did not have supporters.  The results did not change when transfers and 
deaths were excluded from the measurement. Successful treatment outcomes were 
significantly associated with treatment supporters having fewer than 10 patients, patients 
living with someone, patients of age 40 or more years, male patients, those whose highest 
education levels were tertiary and secondary.  
Patients and clinic staff said that supporters were useful in checking on patients’ treatment, 
giving medicine, counselling and advising patients on medication and in practical help.  
Conclusion: Treatment supporters had a significant role in promoting patients’ treatment 
outcomes. It is recommended that TB treatment programme staff should consider using 
treatment supporters in their programmes. 
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Abbreviation and definition of terms 
Adherence The process of taking treatment regularly or patients taking medication as 
prescribed.  
AIDS Acquired Immune Deficiency Syndrome 
CBO  Community Based Organisations 
Clinic supporter/nurse 
  The nurse responsible for TB treatment and management in the clinic 
Community supporters 
People who work either for pay or as volunteers at community level in 
association with clinics to make sure that TB treatment is taken.  
DOTS Directly observed treatment strategy which is a WHO recommended system for 
providing TB treatment that emphasises political commitments, standardised 
diagnosis of pulmonary cases, standardised treatment, recording and reporting 
and adequate drug supplies. New additions include addressing challenges of 
TB/HIV integration and strengthening of health systems, engaging all care 
providers, empowering people with TB and communities, and promoting 
operational research. Once infection cases have been detected using 
microscopy services, clinic nurses and community treatment supporters 
observe and record patients swallowing the correct dosage of anti TB medicines 
and document that the patient has been cured.  
EMM  Ekurhuleni Metropolitan Municipality  
HIV  Human Immunodeficiency Virus 
MDR-TB:  Multi-drug-resistant Tuberculosis which is a laboratory diagnosis of organisms 
that are shown to be resistant to at least isoniazid and rifampicin.  
New TB A patient who has never had treatment for TB or who has taken anti-TB for less 
than one month 
NGO  Non-governmental organisation 
SDC  Service Delivery Centre 
SDR  Service Delivery Region 
SSDR  Southern Service Delivery Region 
TB   TB is an infection by the Mycobacterium tuberculosis organism 
Treatment supporter 
A person engaged in supporting a patient with TB treatment to ensure it is taken   
WHO  World Health Organisation 
XDR-TB Extreme drug-resistant tuberculosis (TB) is caused by poor TB control, through 
taking the wrong types of drugs for the incorrect duration. It is resistance to at 
least isoniazid and rifampin among first-line anti-TB drugs, resistance to any 
fluoroquinolone, and resistance to at least one second-line injectable drug 
(amikacin, capreomycin, or kanamycin).  
Treatment outcomes definitions as outlined in the TB register 
Treatment success 
 Sum of those patients who were cured plus those who completed treatment but 
without bacteriologic proof of cure 
Cured  A patient (initially smear positive) who is smear negative at, or one month prior 
to completion of treatment and on at least one previous occasion. 
Treatment Completed  
Treatment completed without bacteriologic proof of cure 
Interrupted Treatment 
 X 
 
 
 
 
 
Treatment interrupted for two or more months.  
Treatment Failure 
A patient remains or becomes again smear positive at 5 months or later during 
treatment  
Transfer Patient transferred to another district; treatment outcome unknown. 
Death  Death of a patient arising from any cause 
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1.  Introduction  
This study focused on investigating whether the community treatment supporters were 
influencing TB patients’ treatment outcomes. The criteria for assigning a treatment supporter 
to a patient were determined by clinic nurses, treatment supporters and the patients. The 
clinic nurses asked the new patients if they preferred a treatment supporter to assist them in 
TB treatment. The patients who preferred to have treatment supporters were asked to 
choose any treatment supporter in or near their village. The clinic nurse would then inform 
the treatment supporter and ask her/him to assist the patient. If a supporter had more than 
ten patients then the patient was asked to choose another. The treatment supporters were 
attached to the clinics and worked as volunteers in the community. The patients who 
preferred clinic treatment were supported by clinic nurses who administered the intake of TB 
medicine.    
1.1  Ekurhuleni Metropolitan Municipality 
The Ekurhuleni Metropolitan Municipality was established after the municipal elections held 
on 5 December 2000 and is responsible for the area formerly known as the East Rand. It 
includes the following councils; Alberton, Benoni, Boksburg, Brakpan, Edenvale, Germiston, 
Kempton Park, Nigel, Springs and Khayalami. The population is about 2.4 million, in an area 
covering 190,000 hectares. The municipality is situated in South Africa’s economic heartland 
with vibrant mining industries and business activities. The area has experienced an influx of 
immigrants both locally and in international arena. There are a number of informal 
settlements where people live in congested and poor conditions.  
The Municipality has been sub-divided into three Service Delivery Regions (SDRs) namely 
the Southern, Eastern and Northern (figure 1, 2). The project concentrates in the Southern 
Service Delivery Region (SSDR), which includes Germiston (S1), Alberton (S2) and areas of 
Boksburg (S3) (1). The Southern Service Delivery Region has a population of 921 366 
people based on the 2001-population census (2).   
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Figure 1: Map of Southern Service Delivery Region (EMM annual report 2004) 
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Figure 2: Map of Ekurhuleni Metropolitan Municipality (EMM annual report 2004) 
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1.2  Tuberculosis numbers and rates and TB services in the Southern service 
delivery region (SSDR) 
Tuberculosis is a major public heath problem in South Africa. In 2006, the World Health 
Organization ranked South Africa fifth among the world’s 22 high-burden TB countries. 
According to the World Health Organization (WHO) Global TB Report 2006, South Africa had 
nearly 340 000 new TB cases in 2004, with an incidence rate of 718 cases per 100 000 
people – a major increase from 338 per 100 000 in 1998 (3). Since South Africa adopted 
Directly Observed Treatment, Short-Course (DOTS) in 1996, all districts have implemented 
the core DOTS components, although coverage varies widely within and among districts. 
Despite South Africa’s investments in TB control, progress toward reaching program 
objectives has been slow. Treatment success remains low compared with other African 
countries with high HIV/AIDS prevalence and considerably fewer resources. Tuberculosis 
has remained a major health problem in Ekurhuleni Metropolitan Municipality with DOT 
treatment success rates for new smear positive patients falling below 60% (1). National 
treatment success rates in 2003 were 67% with incidence rates of 718/100 000 in 2004 (3) 
Figure 3 and figure 4 shows TB treatment success rates and incidence rates respectively for 
the years 2000 to 2004 in the Southern service delivery region (1, 4).   
 
Figure 3: Southern Service Delivery Region TB success rates 2000–2004 (EMM annual 
reports) 
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Figure 4: Southern Service Delivery Region TB incidence rates from 2000–2004 (EMM annual 
reports) 
 
TB services in the area are provided by 31 clinics. The DOTS strategy was introduced in 
1998 in keeping with the National Health Policy. Clinic staff responsible for TB treatment 
provide DOTS support in the clinics while community supporters provide DOT support at 
patient homes. 
1.3 The role of TB treatment supporters in Ekurhuleni Metropolitan Municipality 
 
There is no reliable information that can guide health professionals and clinic nurses in EMM 
on the role of community treatment supporters. The national policy for community health 
workers assumes that DOT support is part of their role. There is only one study conducted 
on DOTS supporters’ role in Ekurhuleni Metropolitan Municipality (EMM), specifically in the 
Southern Service Delivery Region. Ntsele (unpublished study 2000) conducted a study in 
Germiston on treatment outcomes of patients who had community versus clinic nurses and 
found no statistical evidence of difference in the cure rates between these two groups.  
 
 
 
0 
100 
200 
300 
400 
500 
600 
700 
800 
2000 2001 2002 2003 2004 
Year 
Incidence rates
In
c
id
e
n
c
e
 r
a
te
 p
e
r 
1
0
0
0
0
0
 
 6  
1.4  Literature review  
 
Introduction 
This literature review provides an overview of studies on patient’s adherence to treatment, 
approaches that have been adopted to ensure effective DOTS implementation and 
constraints faced in TB treatment programs.   
 
Tuberculosis is one of the world’s most serious diseases killing approximately 2 million 
people every year, with an estimated 8 million presenting with disease every year (5, 6). The 
World Health Organisation shows that TB burden is on the increase due to a breakdown in 
health services, the spread of HIV/AIDS, poverty and the emergence of multi-drug-resistant 
TB (7). The DOTS strategy was promoted by the STOP-TB partnership in the 2001 as a 
strategy that would improve TB diagnosis and treatment.  
South Africa is burdened by one of the worst tuberculosis epidemics in the world, with 
disease rates more than double those observed in other developing countries and up to 60 
times higher than those currently seen in the USA or Western Europe. The TB situation is 
worrying, as cases of XDR-TB have been identified recently. This strain resists both first- 
and second-line TB drugs; drugs for XDR-TB are not readily available. 
South Africa like other countries that implemented the DOTS strategy has faced challenges 
in TB control. The National TB Control Program (NTP) identified poor patient adherence as a 
factor that contributed to low cure rates (8). One of the problems currently faced by TB 
programs is multi-drug resistance that emanates from incomplete treatment /interruptions. 
The incidence of TB in South Africa has been classified by WHO standards as a ‘serious 
epidemic’ (9). 
The DOTS strategy aims at increasing patient adherence through encouraging active 
participation in the program by health care services and ensuring that “every TB patient has 
the support of another person to ensure that they swallow their medication daily” (8). Both 
treatment supporters and the patients have a role to play in TB treatment adherence. 
Treatment supporters are “expected to motivate and empower patients and their families and 
provide them with a better understanding of TB and the importance of cure” (8). Tuberculosis 
is a curable disease but statistics show that it is still on the increase (6). The DOTS strategy 
within the TB program has been set up to involve communities in prevention and treatment 
of the disease. Many studies have been carried out on improvement of DOTS strategy 
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implementation. Problems that affected adherence were identified as lack of material support 
(food and money), transport costs, family income and stigma (10). Incentives are reported to 
have motivated treatment supporters in their work (11). Kironde et al investigated other 
factors in Cape Town as altruism - especially those patients who had been patients 
themselves or knew people affected by the disease, filling in spare time - particularly for 
younger volunteers, gaining work experience - the attraction of getting good references and 
contacts, the novelty factor - community participation in TB control in the province was 
relatively new (12). Lack of proper coordination of treatment supporters was examined as a 
major determinant in patients’ treatment adherence (13). Other studies have identified 
access to facilities as a factor leading to poor treatment adherence, namely the long 
distances patients walked to clinics to collect medicine (14). However, Dievler and Pappas in 
their analysis of the TB situation in Vietnam singled out lack of basic infrastructure within 
health services, including lack of clinic equipment and cars to follow up patients. They also 
viewed effective communication between supporters and their patients as a way to improve 
treatment adherence (15). Given these facts, it could be possible that the DOTS strategy 
may not achieve its goals because of lack of incentives for treatment supporters, poor co-
ordination with treatment supporters and partial involvement or commitment of patients. 
Treatment supporters are drawn preferably from communities where patients live and 
therefore are in a position to visit and attend to patients effectively. Kleinman says, “Close 
contact with patients can significantly impact on patient’s commitment to a correct regimen” 
(16). Investigating the nature of treatment supporters’ services and their linkages with TB 
clinics would provide evidence of their role in TB treatment.  
Robinson warns, “Case finding and treatment programmes are best not begun unless 
community follow up of patients can ensure that all prescribed treatment is completed” (17). 
Godfrey-Faussett identifies interventions that would make TB programs successful, as active 
case finding in communities and this will prevent the transmission of TB (18). The prevalence 
of tuberculosis in high burden countries can effectively be reduced through enhancing 
access to treatment (19, 20). According to Mantala DOTS strategy achieved good treatment 
outcomes in the Philippines because DOT supporters were involved (21). Godfrey-Faussett 
however indicated that “health services that find it difficult to find cases efficiently will also 
find it difficult to support patients throughout treatment to achieve a cure. Partnerships with 
traditional healers, community based organizations (CBOs) and private practitioners could 
reduce this burden” (18). In Lusaka, Zambia over half of the TB patients received care from 
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community based organizations (18). Direct treatment observation is essential and should 
not be a mechanical procedure of dropping medicine into a patient’s mouth “supervised 
swallowing” (21). Frieden and Driver stated, “Direct observation succeeds by building a 
human bond between a patient and the health care worker or community volunteers” saying 
that it takes both the TB program and community support for successful treatment of TB 
(22). The role of treatment supporters is to ensure patients adherence to TB medication (22). 
A cross sectional study conducted by Maher on “Community TB care in Africa” in the 
following countries - Botswana, Kenya, Malawi, South Africa, Uganda and Zambia found that 
health facilities offering patients the option of community supervised or health centre 
supervised treatment performed effectively (19). Treatment interruption may be caused by 
some patients’ negative perceptions of treatment strategy (23). A study in the sub Saharan 
Africa found that one community based organisation working closely with TB programs 
attained a high treatment completion rate through community participation and involvement 
(24).  
There was a decrease in cure rates experienced in the Southern Service Delivery Region 
from 74% in 2001/2002 to 57% in 2002/2003 (1). This may have been caused by poor 
monitoring of treatment adherence as Robinson identifies that “some patients do not feel it is 
necessary to continue with medication, especially after taking treatment for a few weeks” 
(17). There could be many more reasons why TB treatment programs are failing but it is 
clear that treatment supporters have a role to play in patients’ adherence to treatment and 
that if this is well implemented; better TB cure rates are likely.  
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1.5 Aims and objectives of the study 
 
Aim 
This study aimed to investigate the role of treatment supporters for patients on TB treatment.   
 
Objectives 
 
For new TB patients with and without treatment supporters, who were registered six months 
before the study at clinics in the Southern Service Delivery Region (SSDR) of Ekurhuleni 
Metropolitan Municipality.  
 
1. To document their demographic characteristics, experiences and problems related to 
taking TB treatment 
2. To compare their TB treatment outcomes 
3. To examine patient and service factors that were associated with successful treatment 
outcomes 
4. To document experiences and problems and suggestions of treatment supporters of 
those patients who had supporters 
5. To describe the role of treatment supporters, problems of supporters and suggestions to 
improve TB treatment stated by TB staff of the clinics 
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2.  Methods 
 
Introduction 
This chapter describes how the questionnaires were designed, the manner in which the 
study subjects were recruited, describes the data collection tools and the ethical 
considerations. 
2.1 Study Area 
The area of coverage was the Southern Service Delivery Region (SSDR) of Ekurhuleni 
Metropolitan Municipality. It is situated in the Eastern part of Gauteng Province, about 20 KM 
away from Johannesburg city. It is a densely populated industrial region which includes 
Thokoza, Boksburg, Germiston, Katlehong and Vosloorus towns. The SSDR was sub-
divided into Service Delivery Centres (SDC) namely Germiston (S1), Alberton (S2) and 
Boksburg (S3) for administrative purposes. The study focused on the TB clinics providing 
treatment on daily basis in this region. There were 16 clinics in Germiston, six in Alberton 
and nine in Boksburg with a total of 31 clinics in the region.  
2.2  Study design 
 
A descriptive research design was adopted for this study. 
2.3  Study population 
• Patients 
The patient study population was 115 TB patients with treatment supporters and 101 without. 
They were all adults (18 years of age and over) in the defined category of ‘new’ patients 
diagnosed with any type of TB and who had been registered at clinics in the SSDR of the 
Ekurhuleni Metropolitan Municipality six months before recruitment into the study. Those 
excluded were children under 18 years, those on the re-treatment category and MDR 
patients.   
• Treatment supporters of the patients who had supporters. 
• Staff members primarily responsible for TB patients at the clinics 
2.4 Study sample 
Patients 
The 31 TB clinics in Ekurhuleni Metropolitan Municipality were written in pieces of paper, 
picked at random and listed in each of their respective Service Delivery Centres in the 
Southern Service Delivery Region (SSDR) where the study was based. Germiston (S1) had 
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sixteen clinics with 376 patients, Alberton (S2) had six clinics with 140 patients and Boksburg 
(S3) had nine clinics with 274 patients. The population of all “new” adult TB patients 
registered in the clinics was therefore 790. These patients were numbered in their respective 
Service Delivery Centres as shown in table 1 below. 
Table 1: Sampling frame 
Germiston Service Delivery Centre (S1) 
Clinic No of patients registered in April and May 2006 Cumulative range 
Dukathole 31 1-31 
Zonkizizwe I 27 32-58 
Zonkizizwe II 17 59-75 
Moleleki 49 76-124 
Elsburg Clinic 22 125-146 
Goba Clinic 52 147-198 
Katlehong North  20 199-218 
Motsamai 33 219-251 
Khumalo  17 252-268 
Leondale 19 269-287 
Germiston City  25 288-312 
Palmridge 15 313-327 
Ramokonopi 11 328-338 
Magalula 9 339-347 
Tamaho 21 348-368 
Sunriseview 8 369-376 
Alberton Service Delivery Centre (S2) 
Clinic No of patients registered in April and May 2006 Cumulative range 
Brackenhurst 21 1-21 
Phola Park 32 22-53 
Dresser 27 54-80 
Edenpark 10 81-90 
Penduka 28 91-118 
Alberton North 22 119-140 
Boksburg Service Delivery Centre (S3) 
Clinic No of patients registered in April and May 2006 Cumulative range 
Dawn Park 12 1-12 
Boksburg Civic Cent 27 13-39 
Reiger Park 42 40-81 
J. Dumane CHC 53 82-134 
Tswelopele 18 135-152 
Vosloorus Ext 14 16 153-168 
Vosloorus Ext 28 31 169-199 
Vosloorus Poly 46 200-245 
Vosloorus Ext 9 29 246-274 
 
The sampling procedure  
A multi stage sampling method using probability proportional to size was used in order to 
give patients registered at clinics with large numbers the same probability of being selected 
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as patients registered at clinics with smaller numbers (the number of units Mi in the i
th cluster 
forming a measure of size). Two clinics (M=2) were sampled from each SDC using the 
following systematic sampling: the population of patients listed in each SDC was divided by 
two to obtain a sampling interval involving the selection of every kth patient from the sampling 
frame, where k, was the sampling interval. From the sampling frame, a starting point was 
chosen at random between one and the sampling interval (SI), and choices thereafter were 
at regular intervals. The other random number was obtained by adding the sampling interval 
to the first random number selected. These numbers represented patients and were used to 
trace the clinics where the patients with those numbers attended. Two clinics were selected 
from each of the three Service Delivery Centres using this sampling method resulting in six 
clinics being selected.  
The sampling interval for Germiston SDC was 376/2= 188 and the random start number was 
111 and the second number was 111+188= 299.  Patient numbers 111 and 299 were 
registered in Moleleki and Germiston city clinics respectively.  
Alberton SDC’s sampling interval was 140/2 = 70, random start number chosen was 37 and 
the second random number was 37+70=107. Two patients with numbers 37 and 107 in the 
list were registered in Phola Park and Penduka clinics respectively.  
For Boksburg SDC the sampling interval was 274/2 = 137, random start number was 79. The 
second random number was 79+137= 216. Patient numbers 79 and 216 were from 
Vosloorus Poly clinic and Reiger Park clinic. The two clinics selected in Germiston SDC had 
74 registered, those in Alberton SDC had 60 and in Boksburg 88 patients, making a total of 
222 TB patients in the sample.  
Treatment supporters 
The study sample comprised all the treatment supporters of sampled patients in the six 
selected clinics  
TB clinic staff 
Each of the six selected clinics had one staff member who was responsible for TB. All six 
were studied. 
2.5  Measurements 
The researcher requested the nurse responsible for TB in each of the six selected clinics to 
introduce the study to patients and supporters during their routine meetings in the clinics.  
They were then invited by the researchers to participate and to be interviewed. The 
interviews took about ten minutes and were conducted between the 20th and 30th October 
 13  
2006. The interviewers were four qualified auxiliary social workers who were researcher’s 
colleagues and were not treatment supporters in the clinics. They were trained on data 
collection tools to ensure validity and accuracy of the tools. They all lived in Germiston and 
travelled to the clinics using public transport.  The patients attending clinics were identified 
when they attended. Those who did not attend clinics themselves were visited in their homes 
for interviews.  The interview forms are attached in appendix 2. 
Patient Data  
Patient data was obtained from interviews. The following variable were collected on each 
patient: patient numbers at each clinic, age, gender, whether living with a partner or living 
alone, educational level reached٭, number of patients per supporter, patient knowledge 
about the duration of their treatment*, their  experiences in taking TB treatment, the type of 
TB, how they accessed treatment, any stated problems. Patients with a supporter were 
asked about the type of supporter and frequency of visits (patients to clinics or between 
patients and supporters), the role of the treatment supporter as they experienced it and the 
perceived usefulness of the supporter. The number of patients per supporter was 
ascertained from clinic staff. 
Note: 
٭Educational level reached was categorised into four groups where non-formal education 
included all patients with 0 or only 2 grades, primary education included all patients who 
reached  grade 3–7, secondary education for those who reached grade 8–12 and tertiary 
grade after grade 12.  
* Patients’ knowledge of the duration of their treatment was assessed according to the type 
of TB.  For pulmonary and all types except TB meningitis, miliary and bone TB, correct 
duration was noted if patients said six months, incorrect if they said less or more.  For TB 
meningitis and miliary TB, correct duration was nine months and for bone TB, correct was 
accepted for nine to twelve months.  
Treatment outcomes 
The treatment outcome of each patient was documented from clinic registers and compared 
for patients with and without a treatment supporter. The treatment outcomes were defined 
according to the national TB control programme (8): cured, completed, failure, death, 
transferred and interrupted. In addition, treatment outcomes were compared for patients of 
different age groups and genders, patients living with someone or living alone, with correct 
knowledge about treatment duration, patients for whom supporters collected their treatment 
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from clinics rather than collecting it themselves, their educational status and whether they 
had clinic or community supporters. 
Treatment supporter Interviews 
Each treatment supporter was interviewed. Variables measured were demographic 
characteristics (gender, age, level of education), outcomes of supported patients, number of 
treatment supporters per interviewer, their knowledge and experiences of TB treatment, 
duration of home visits, meetings between supporters and clinic staff, patient problems, ways 
in which they supported the patients, the frequency of contact with patients, their role, 
suggestions for improvement and any difficulties faced by supporters in assisting TB 
patients.   
Interviews with TB clinic staff 
The clinic staff responsible for TB were interviewed. The variables measured were the 
position of the staff in the clinic, training of supporters, clinic policies, role of treatment 
supporters as observed by clinic staff, problems of patients, staff opinions about the 
usefulness of supporters, ways in which treatment supporters work could be improved, the 
role of TB staff in assisting patients and treatment supporters, meetings with treatment 
supporters and other ways apart from supporters in which TB treatment could be improved. 
2.6 Ethical Considerations 
The researcher ensured that patients’ rights were observed. There was no any harm, pain or 
embarrassment caused to the subjects. The purpose of the research was explained to all the 
subjects and they were requested to sign an informed consent form attached in appendix 3.  
The confidentiality was ensured to the uttermost and was agreed upon before the study 
commenced. Privacy of individuals was not infringed and the respondents had the right to 
refuse to participate or answer particular questions without any prejudices to their treatment. 
The investigator and the nurse responsible for TB in the clinics carried out all records review. 
Care was taken not to reveal/include any names in the report. Ethical clearance and 
permission to carry out the study was obtained from: 
• University of Witwatersrand Ethical Committee: Protocol number MO60633 
• Ekurhuleni Metropolitan Municipality 
Human research ethics committee clearance certificates are attached in appendix 4. 
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2.7 Pilot study 
 
A pilot study was conducted in Goba clinic, a clinic other than those sampled for the study 
before any data collection was carried out in the study sample. The pilot study helped to 
identify the strengths and weaknesses of the interview questions and corrections were made 
accordingly. It provided a trial to test the interviewers’ ability to accurately use the tools and 
where they needed re-training before the actual exercise. The pilot study highlighted the 
need to assign each interviewer in a specific clinic for five days as opposed to original plan of 
placing the four of them in one clinic per day.  
2.8 Data Processing and Data Analysis 
 
The data was pre-coded and entered directly into Epi Info version 3.3.2. The variables were 
classified in a number of ways and defined as numeric, multiline, text, and date depending 
on the variable type. The data entry incorporated checks and automatic coding in order to 
enforce quality control by setting rules and conditions, for example the number of 
unsuccessful outcomes was equal to number of deaths and treatment interruptions, also the 
number of patients cured was less than the number of patients registered at the clinic. 
Before data analysis was conducted, the write and merge commands were used to clean up 
data table that contained undesired information for instance it was used to recode the values 
of clinics that were misspelled during the data entry. Missing values for each variable was 
checked through conducting frequency tables of variables and summarizing the variables, 
this specifically helped to correct missing values in sex and educational status. The data was 
analysed for frequencies and compared using tests for significance (Chi-square). Analysis of 
single table was conducted for odds ratio at 95% confidence limits Cornfield, Chi-square 
Yates correction was used as it was more appropriate for the study and its associated p-
value gave a statistically significant difference between the two variables measured if p-value 
< 0.05.   Treatment outcomes for the two patients groups were, compared against treatment 
outcomes at the end of six months to determine any statistical significance.  
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3. Results 
 
Introduction 
The results are described in this chapter using tables, figures and in narrative form. This 
chapter has been sub divided into three sections highlighting responses from TB patients, 
treatment supporters and clinic staff. It presents the results on treatment outcomes, 
experiences and knowledge about TB treatment, method of accessing treatment and 
problems experienced in treatment, role and usefulness of treatment supporters and ways of 
improving treatment support.   
3.1  TB patients 
3.1.1 Response rate 
There were 222 patients sampled, 216 patients were interviewed and six refused to 
participate. The response rate was thus 97%. Four patients who refused to participate had 
no supporters and four of these had interrupted their treatment. Three were registered at 
Reiger Park clinic as shown in Table 2. 
Table 2: Characteristics and treatment outcomes of pts who refused to be interviewed 
Age in years Gender Clinic Treatment Supporter Treatment Outcome 
19 Female Vosloorus Poly Yes Completed 
24 Male Penduka No Interrupted 
26 Male Reiger Park No Interrupted 
31 Male Phola Park No Cured 
33 Female Reiger Park Yes interrupted 
34 Male Reiger Park No Interrupted 
3.1.2 Number of patients per interviewer 
The number of patients interviewed by each of the four interviewers were 72 (33%), 58 
(27%), 49 (23%) and 37 (17%) respectively. 
3.1.3 Patient characteristics 
Gender 
Table 3 illustrates the number and proportion of patients with and without treatment 
supporters by gender. There were more males than females (56% and 44% respectively). 
The proportion of male and female was similar for patients with and without supporters. 
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Table 3:  Gender distribution of patients 
Gender Patients with supporter 
N (%) 
Patients without supporter 
N (%) 
Total N (%) 
Male  65 (54%) 56 (46%) 121 (56%) 
Female 50 (53%) 45 (47%) 95 (44%) 
Total 115 (53%) 101 (47%) 216 (100) 
Age 
Most patients (65%) were between 30 and 64 years of age as shown in Table 4. The mean 
age of the patient respondents was 34.4 years (S.D=10.6) with a range of 18-66 years, a 
median of 32 years and a mode of 31 years.  
 Table 4:  Age distribution 
Age category in years Patients N (%)                                     
18-29 8 (4%) 
30-49 141 (65%) 
50-64 57 (22%) 
65+ 10 (7%) 
Total 216 (100%) 
Patients living with someone or living alone 
Patients were categorised as living alone (single, divorced, widowed or separated) or living 
with someone (married, staying with partner, relative or friend). There was no significant 
association between supported and unsupported patients and whether they lived alone or 
not (OR=0.64, X²=0.89, p=0.34). The results are shown in table 5. 
 
Table 5:  Patient living with someone or living alone 
Living status With supporter n (%) Without 
supporter n (%) 
Total (n) 
Living with someone  95 (52%) 89 (48%) 184 (85%) 
Living alone 20 (63%) 12 (37%) 32 (15%) 
Total 115 (53%) 101 (47%) 216 (100%) 
3.1.4 Patient numbers per clinic 
The least number 14 (12%) of supported patients were in Phola Park and the greatest 25 
(22%) in Vosloorus clinic.  There was a greater proportion of unsupported patients in three 
clinics namely Reiger Park 34 (34%), Penduka 29 (29%) and Phola Park 19 (19%), while in 
Germiston, Moleleki and Vosloorus the proportion who had supporters was greater as 
illustrated in Table 6 below. 
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Table 6:  Number of patients per clinic 
Name of clinic With supporter n (%) No Treatment supporter n (%) Total n (%) 
Phola Park 14 (42%) 19 (58%) 33 (15%) 
Reiger Park 16 (32%) 34 (68%) 50 (23%) 
Penduka 19 (40%) 29 (60%) 48 (22%) 
Germiston 20 (83%) 4 (17%) 24 (11%) 
Moleleki 21 (68%) 10 (32%) 31 (15%) 
Vosloorus 25 (83%) 5 (17%) 30 (14%) 
Total 115 (53%) 101 (47%) 216 (100%) 
3.1.5 Types of TB  
Table 7 shows the distribution of patients by each type of TB. The majority of patients (187 
or 87%) had pulmonary TB. A higher proportion (59%) with miliary and meningitis TB were 
without supporters.  
Table 7:  Types of TB 
Type of TB  Supporter n (%) No supporter n 
(%) 
Total    (n) 
Pulmonary TB 102 (54%) 85 (46%) 187 (87%) 
Miliary and Meningitis TB 11 (41%) 16 (59%) 27 (12%) 
TB bone 2 (100%) 0 (0%) 2 (1%) 
Total 115 (53%) 101 (47%) 216 (100%) 
3.1.6 Patient Knowledge and experiences 
Duration of TB treatment 
Most patients (129 or 69%) with pulmonary TB had correct knowledge of their treatment 
duration, but 58 (31%)  did not; 12 patients stated duration less than six months and 46 
patients said more than six months. A chi square test showed a significant association 
between patients who stated six months duration of treatment and being supported 
(OR=2.17, X²=5.13, p=0.02). Details are displayed in table 8. 
Table 8:  TB treatment duration takes six months 
Knowledge about duration of treatment  
Correct Incorrect 
Total    (n) 
Supporter  78 (60%) 24 (41%)  102 (54%) 
No supporter 51 (40%) 34 (59%) 85 (46%) 
Total 129 (69%)  58 (31%)  187 (100%) 
A total of 19 patients (70% of 27) with miliary and meningeal TB correctly stated 9-12 
months. Correct knowledge of those with non-pulmonary TB was significantly associated 
with having a supporter (OR=0.32, X²=8.58, p=0.0034). 
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• Knowledge about treatment duration at different clinics 
Fifty-eight patients (31% of all) stated incorrect duration periods for their treatment. The two 
clinics in the Boksburg Service Delivery Centre had the highest number of patients with 
correct knowledge of six months treatment duration 52 (40% of 129) according to table 9 
while Phola Park clinic had the highest proportion of patients who stated the incorrect 
duration – more of less than six month (16 patients or 28% of 58). Table 8 illustrates the 
results.  
Table 9: Knowledge of treatment duration of patients with pulmonary according to 
clinic in service delivery centres 
Clinic < 6 months n (%) 6 months n (%) 6+ months n (%) Total N (%) 
Germiston٭ 1 (7% of 12) 11 (73% of 129) 3 (20% of 46) 15 (8% of 187) 
Moleleki٭ 0 (0%) 26 (84% of 129) 5 (16% of 46) 31 (16% of 187) 
Penduka٭٭ 2 (5% of 12) 31 (76% of 129) 8 (19% of 46) 41 (22% of 187) 
Phola Park٭٭  4 (16% of 12) 9 (36% of 129) 12 (48% of 46) 25 (13% of 187) 
Vosloorus٭٭٭ 3 (10% of 12) 21 (72% of 129) 5 (17% of 46) 29 (16% of 187) 
Reigerpark ٭٭ ٭  2 (4% of 12) 31 (67% of 129) 13 (28% of 46) 46 (25% of 187) 
Total 12 (6% of 187) 129 (69% of 
187) 
46 (25% of 187) 187 (100%) 
٭ Germiston Service delivery centre 
٭ ٭Alberton Service delivery centre 
٭ ٭ ٭ Boksburg Service delivery centre 
• Highest level of education achieved  
Out of the two hundred and sixteen patients interviewed, 9 (4%) had no formal schooling, 54 
(25%) had reached primary level, 141 (65%) patients had attained secondary level of 
education and 12 (6%) had studied up to tertiary level. Education and the knowledge of 
duration are shown in Table 10. A chi square test showed that patients knowledge of 
treatment duration did not associate with non-formal education (p=0.067). The proportion of 
patients with correct knowledge clearly increases with increasing education categories. 
There was a significant association between patients with tertiary and secondary education 
with their knowledge of TB treatment duration (p=0.02). 
Table 10:  Educational level and knowledge of treatment duration  
Level of education Correct duration 
n (%) 
Incorrect duration 
n (%) 
Total    n (%) 
Non-formal education 3 (33 of 9%) 6 (67% of 9) 9 (2%) 
Primary education  41 (76% of 54) 13 (24% of 54) 54 (25%) 
Secondary education 99 (70% of 141) 42 (30% of 141) 141 (67%) 
Tertiary education 11 (92% of 12) 1 (8% of 12) 12 (6%) 
Total 154 (72% of 216) 62 (28% of 216) 216 (100%) 
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• Problems faced by patients in TB treatment 
Problems experienced in TB treatment as stated by patients can be seen in table 11. The 
results showed that 47% of 556 responses to this question stated that they were 
experiencing symptoms. A higher proportion of patients without supporters were 
unemployed, otherwise there was no difference in stated problems as categorised between 
supported and unsupported patients.    
Table 11: Problems stated by patients in taking TB treatment 
Patients with 
supporters  
Patients without 
supporters  
Total responses Stated problems 
N % N % N % 
Experienced symptoms  151 48 111 46 262 47 
Lack of food 37  12 36  15 73 13 
Unemployment 28  9 40  17 68 12 
Lack of transport to clinic 27  9 17  7 44 8 
Poor family attitudes 29 9 11 5 40 7 
Poor community attitudes 20  6 10  4 30 6 
Need to take time off 
work to attend clinics 
14  4 12  5 26 5 
Bad clinic staff attitudes 8  3 5  1 13 2 
Total responses 314 100 242 100 556٭ 100 
٭ Some patients gave more than one answer 
3.1.7 Type of treatment supporter and frequency of supporter contact 
Table 12 shows the type of supporter and frequency of visits. Of those patients who were 
supported, a total of 78 of 115 (68%) of patients had community supporters while 37 (32%) 
patients had clinic nurses. The frequency of patients’ daily contacts with the clinic staff was 
higher than with the community treatment supporters (86% versus 76%). The proportion of 
patients who were observed on daily basis was 79%.  
 
Table 12: Type of supporter and frequency of visits 
Frequency of visits٭ Type of 
supporter  
Daily 2-3 times a 
week 
Weekly  2 times a 
month 
Monthly  
Number of 
patients N 
(%) 
Clinic nurse      
N (%) 
32 (87%) 0 (0%) 3 (8%) 1 (3%) 1 (3%) 37 (32%) 
Community 
Supporter  
59 (76%) 4 (5%) 9 (12%) 4 (5%) 2 (2%) 78 (68%) 
Total 91 (79%) 4 (4%) 12 (10%) 5 (4%) 3 (3%) 115 (100%) 
٭ visits mean the number of contacts patients had with their supporters 
 
  
 
 
 21  
 
• Number of patients per supporter 
The mean number of patients supported by one treatment supporter was 9.7 (SD=3.5) with a 
range of 5-20, a median and mode of 10. Three supporters had 10 or more patients and 27 
had fewer than 10 patients.  
• Treatment access for patients with supporters 
Most supported patients 73 (63% of 115) collected their own TB treatment from clinics, 
supporter visited 59 (51% of 115) of them at home and 14 (12% of 115) patients were going 
themselves to the supporter. Forty-two (37% of 115) patients had their medication collected 
by supporters, who visited 16 (14% of 115) at home and 27 (23% of 115) went themselves to 
the supporter.  
3.1.8 Role of Treatment Supporters 
Patients’ responses on the role of treatment supporters were grouped in three categories as 
shown in Table 13 below. Medication and counselling included roles such as checking on 
patients’ treatment, giving medicine, reminding patients about clinic days, counselling and 
advising patients on medication. Coordination, monitoring and reporting comprised the 
following roles; asking about patients’ progress, attending meetings and giving reports to 
clinics. Practical help covered relocating patients, accompanying patients to clinic, food 
preparation and washing of weak patients.   
Table 13: Role of treatment supporters 
Category of roles Respondents per answer   N (%) 
Medication and counselling 93 (57%) 
Coordination, monitoring and Reporting 65 (40%) 
Practical help 4 (3%) 
Total responses 162 (100%) 
٭ Some patients gave more than one answer 
3.1.9 Usefulness of treatment supporters 
Supported patients were asked whether they found their treatment supporters useful in 
helping them in TB treatment. One hundred and three of the 110 patients that answered this 
question (94%) patients agreed that treatment supporters were useful while seven (6%) 
disagreed for the following reasons: the supporters failed to talk to family members of three 
patients to change their poor attitude towards them, two said they did not need the services 
of a supporter, one indicated that the treatment supporter forced him with medicine and 
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another one said that the supporter was bothersome. Five patients refused to answer this 
question.  
3.1.10  Visits between patients and supporter 
Patients stated that patients and supporters interacted specifically for treatment support. 
However, 45 (39%) patients indicated that they visited their supporters at other times. In 
these visits, they had discussions on ways of accessing government social grants, education 
of their children, how TB had affected business activities, the role of church in helping the 
patients and relocation to a rural area. 
Table 14: Summary of variables compared for supported and non supported patients  
Variable category P value of association 
Tertiary and secondary education vs knowledge of 
treatment duration 
0.02* 
Knowledge about treatment duration 0.02* 
Knowledge about treatment duration vs non-formal 
education 
0.067 
Patients living with someone vs living alone 0.34 
*Statistically significant in X² test comparing variables with supported and unsupported patients  
3.1.11  Treatment outcomes 
• Treatment outcome by supporter and no supporter 
Treatment outcomes of all patients are shown in Table 15.   
Table 15: TB Treatment outcomes 
Treatment outcomes n (%) Total  Patient 
category Cured  Treatment 
completed  
Transfer  Interrupt.  Treat. 
failure 
Deaths N (%) 
With 
supporter  
59 (51%) 22 (20%) 12 (10%) 8 (7%)  8 (7%) 6 (5%)  115 (53%) 
Without 
supporter 
36 (36%) 15 (15%) 14 (14%) 13 (13%) 12 (12%) 11 (10%) 101 (47%) 
Total 95 (44%) 37 (17%) 26 (12%) 21 (10%) 20 (9%) 17 (8%) 216 (100%) 
 
Treatment outcome success was obtained from combining the cured and completed 
outcomes categories. Significantly more successful outcomes were measured in patients 
who were supported (OR=2.34, X² = 8.18, p =0.0042).  
It was found that even when the 26 transfers were excluded, patients who were supported 
were more likely to achieve successful treatment outcomes (OR=2.60, X² = 7.99, p =0.0047), 
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and when transfers and deaths were excluded the same association remained (OR=2.48, X² 
= 5.46, p =0.019).  
Treatment outcomes were compared for patients of different age groups and genders, 
patients living with someone or living alone, with correct knowledge about treatment 
duration, patients for whom supporters collected their treatment from clinics rather than 
collecting it themselves, their educational status and whether they had clinic or community 
supporters.  Patients who had died 17 (8%) by the time of the interviews were included.    
A total of 26 (12%), transferred to clinics outside the study region, 12 of whom were 
supported and 14 were not. The treatment outcomes of these patients were therefore 
indeterminable and were thus excluded from further analysis.  
• Number of patients per supporter 
Treatment supporters with fewer than ten patients were more likely to achieve successful 
treatment outcomes than those who had more than ten patients (OR=6.99, X² =13.69, p 
=0.00022). Table 16 compares outcomes of supporters with 10 or more patients. 
Table 16: Supporters with 10+ or <10 patients 
Patients per supporter Successful outcomes 
n (%)       
Unsuccessful 
outcomes n (%)  
Total N  
<10 62 (90%) 7 (10%) 69 (67%) 
10+ 19 (56%) 15 (44%) 34 (33%) 
Total 81 (79%) 22 (21%) *103 (100%) 
* 12 of the 115 patients were excluded as explained above 
• Patients living with someone or living alone 
Table 17 shows treatment outcomes for patients living with someone. It was found that 
patients living with someone were more likely to achieve treatment success than patients 
living alone (OR=5.68, X² = 18.8, p =0.000015). 
Table 17:  Outcomes of patients living with someone or living alone 
Living status Successful outcomes 
n (%) 
Unsuccessful 
outcomes n (%) 
Total (n) 
Living with someone  120 (76%) 37 (24%) 157 (83%) 
Living alone 12 (36%) 21 (64%) 33 (17%) 
Total 132 (70%) 58 (30%) 190 (100%) 
* Excludes 26 patients as explained above 
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• Supporter fetching medicine from clinics for patients  
 
The treatment outcomes was more likely to be successful if the treatment supporters fetched 
medicine for patients from clinics than when patients collected own treatment from the clinics 
(OR=4.16, X² = 7.2, p =0.0073). This data is shown in table 18.   
 Table 18: Supporter collecting patients’ treatment from clinics 
Treatment outcomes  Successful 
outcomes n (%) 
Unsuccessful 
outcomes n (%) 
Total N (%) 
Supporter fetches  
 
57 (88%) 8 (12%) 65 (63%) 
Patient fetches 24 (63%) 14 (37%) 38 (37%) 
Total 81 (79%) 22 (21%) 103 (100%) 
 
• Type of supporter 
 
Table 19 shows the data for treatment outcomes of patients supported by clinic staff and 
community supporters. Successful outcomes and the type of supporter (clinic or community) 
were not associated (OR=0.42, X² = 2.36, p =0.12).  
Table 19: Clinic staff and community supporters’ outcomes 
Type of supporter Successful 
outcomes  
Unsuccessful 
outcomes  
Number of 
patients n (%) 
Clinic nurse n (%) 24 (68%) 11 (32%) 35 (34%) 
Community supporter n (%) 57 (84%) 11 (16%) 68 (66%) 
Total 81 (79%) 22 (21%) 103 (100%) 
• Educational status and outcomes 
There was a significant association between successful treatment outcomes and higher 
educational status. Comparisons were for secondary and tertiary education compared with 
non-formal and primary education (OR=0.26, X² = 13.74, p =0.00021). There was no 
association between successful treatment outcomes and non-formal education compared 
with all other education levels (OR=0.12, X² = 2.41, p =0.067). Educational status and 
outcomes are shown in table 20. 
Table 20:  Educational status and treatment outcomes  
Level of education Successful 
outcomes n (%) 
Unsuccessful 
outcomes n (%) 
Patients n 
(%)                                    
Non-formal and primary 22 (47%) 25 (53%) 47 (25%) 
Secondary and tertiary 110 (77%) 33 (23%) 143 (75%) 
Total 132 (70%) 58 (30%) 190 (100%) 
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• Gender 
In Table 21 are the treatment outcomes by gender showing that males were more likely to 
achieve successful treatment than females (OR=3.22, X² = 11.97, p =0.00054).  
 
Table 21:  Treatment outcomes by gender 
Gender Successful outcomes 
N (%) 
Unsuccessful treatment outcomes 
N (%) 
Total N (%) 
Male  83 (81%) 20 (19%) 103 (54%) 
Female 49 (56%) 38 (44%) 87 (46%) 
Total 132 (70%) 58 (30%) 190 (100) 
• Age 
 
Patients of 40 year of age and more were more likely to have successful treatment outcomes 
than patients under 40 years of age (OR=5.11, X² = 23.15, p =0.000015) as shown in table 
22. No significant differences were found for patients 30 years of age and more or less than 
30 years (OR=0.85, X² = 0.06, p =0.81), patients age category 50 years and above or less 
than 50 years (OR=0.99, X² = 0.02, p =0.89) and for patients age less than 60 years or 60 
years and above (OR=2.22, X² = 1.73, p =0.15). 
Table 22:  Treatment outcome by age 40+ or <40 years 
Age in 
years 
Successful outcomes 
N (%) 
Unsuccessful treatment outcomes 
N (%) 
Patients N 
(%)                                    
40+ 92 (84%) 18 (16%) 110 (58%) 
<40 40 (50%) 40 (50%) 80 (42%) 
Total 132 (70%) 58 (30%) 190 (100%) 
 
• Duration of TB treatment and treatment outcomes 
 
The outcomes of patients who stated the correct duration of their TB treatment were 
compared with those who were incorrect as shown in table 23.  
Those who were correct were more likely to have successful treatment outcomes (OR=4.34, 
X² = 18.28, p =0.00002).  
Table 23:  TB treatment duration correct or incorrect 
Treatment 
duration 
Successful outcomes N 
(%) 
Unsuccessful treatment 
outcomes N (%) 
Patients N 
(%)                                    
Correct 102 (79%) 27 (21%) 129 (69%) 
Incorrect 27 (47%) 31 (53%) 58 (31%) 
Total 129 (69%) 58 (31%) 187 (100%) 
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Table 24: Summary of relationship of defined variables and treatment outcomes  
Variable category P value of association 
Supported vs non supported patients (all patients) 0.0042* 
Supported vs non supported excluding transfers 0.0047* 
Supported vs non supported excluding transfers and deaths 0.019* 
Supporters with <10 vs 10+ patients 0.00022* 
Age 40+ vs other age categories 0.000015* 
Gender (Males vs females) 0.0005* 
Tertiary and secondary education vs other educational 
levels 
0.00021* 
Patients living with someone vs living alone 0.000015* 
Supporter fetches treatment vs patient fetches treatment 0.0073* 
Correct knowledge about treatment duration 0.00002* 
Age 30+ vs other age categories 0.81 
Age 50+ vs other age categories 0.89 
Age 60+ vs other age categories 0.15 
Non-formal vs other education levels 0.067 
Clinic vs community supporter 0.12 
*Statistically significant in X² test comparing variables with treatment outcomes 
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3.2. Treatment supporters 
3.2.1 The response rate 
There were a total of 30 supporters for the 115 patients who were supported. All were 
interviewed 100% response rate). Three interviewers interviewed eight treatment supporters 
each and one interviewed six.  
3.2.2 Characteristics of treatment supporters 
Gender 
A higher proportion 26 (87%) treatment supporters were females while only 4 (13%) were 
males.  
Age 
The mean age of the treatment supporters interviewed was 40.7 years (S.D=12.9) with a 
range of 26-77 years, a median of 38.5 years and a mode of 28 years. The age distribution is 
shown in Table 25. 
Table 25: Distribution of Treatment Supporters by age 
Age range in years Treatment supporters 
 Frequency=n  Percentage (%) 
18-29 5 17 
30-49 19 35 
50-64 3 7 
65+ 2 7 
Total 29 100 
3.2.3 Knowledge and experiences of treatment supporters 
 
• Knowledge about duration of TB treatment 
Most treatment supporters 26 of the 30 (87%) said that TB treatment for pulmonary TB 
should take six months while the four (13%) said more than six months. A total of 18 (67% of 
26) patients supported by supporters with incorrect knowledge did not give the correct 
duration of TB treatment. 
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• Difficulties faced by supporters in their work 
The treatment supporters had faced difficulties in assisting patients in matters relating to 
medication and food. Details are in Table 26. 
Table 26: The difficulties faced by supporters in assisting TB patients 
Difficulties in treatment support Number of supporters n (%) 
Medication and food                                                       
Patients complain of no food, side effects of drugs, 
TB treatment time consuming 
50 (53%) 
Relationship and communication                                                        
No cooperation from patients, patient not at home, 
do not attend at supporters home, alcohol and 
substance abuse 
22 (23%)
Myths and stigma                                                
Myths about TB in community and stigma of TB in 
community 
15 (16%) 
Other problems                                                           
Patient with no permanent homes, no identity books 
7 (8%) 
Total Supporter Responses  94 (100%)* 
*Some supporters gave more than one answer 
3.2.4. Duration of home visits 
Treatment supporters were asked how long it took them to attend to patients during the 
home visits. Fifteen (50%) stated that it took them less than 30 minutes to attend to one 
patient, seven (23%) 30-60 minutes, two (7%) 1-2 hours and six (20%) said that it depended 
on the condition of the patient and ranged between two and three hours.  
3.2.5  Meetings between supporters and clinic staff  
Twenty eight treatment supporters said they had meetings with clinic TB staff, once a month 
for 22, every two weeks for 1 and weekly for 5. Two did not go to the meetings. 
3.2.6 Patient problems 
Patients’ problems as stated by the treatment supporters were similar to those stated by the 
patients themselves.  
 
 
 
 
 29  
3.2.7  Role of Treatment Supporters 
Medication and counselling of patients came out as the major role that treatment supporters 
perceived for themselves. This is presented in Table 27.  
Table 27: Supporters view of their role 
Category of supporter roles Total N (%) 
Medication and counselling                       
Educate/talk/counsel patients about taking medicine, watch them take pills, 
encourage patients 
68 (54%) 
Practical help 
Take food to patients, cleaning of patient houses, wash bed ridden 
40 (32%) 
Coordination, monitoring and Reporting                  
Write/tick on card when pills taken, assist in application for government 
social grants 
17 (14%) 
Total responses *125 (100%) 
*Some supporters gave more than one answer 
 
3.2.8 Suggestions on how the role of treatment could be improved 
Treatment supporters suggested ways their role could be improved; incentives, more training 
and extra resources are mostly listed. These are listed in Table 28. 
Table 28: Supporter suggestions for improving their roles  
Suggestion of supporters Treatment 
Supporters N (%) 
Incentives                                     
Increase pay, stipend payment in time 
 
26 (24%) 
More training  24 (22%) 
Extra resources e.g. kits, badges 21 (20%) 
Patient care 
Provide transport to clinic for bedridden patients 
Provide food to patients 
 
19 (18%) 
 
Recognition                            
Appreciation from clinic staff, recognition from government 
 
14 (13%) 
Other٭ 3 (3%) 
Total Responses **107 (100%) 
٭ Open clinics nearer to communities, employ more nurses, patients choice for supporters. 
** Some supporters gave more than one answer 
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3.3. Clinic staff 
3.3.1  Response rate 
The staff responsible for TB in all the six clinics were interviewed.   
3.3.2 Position of staff 
There was a professional nurse at each of the three clinics Germiston, Reiger Park and 
Penduka clinics, a nursing assistant at each of Moleleki and Phola Park clinic and a primary 
health care nurse at Vosloorus Poly Clinic.  
3.3.3 Training of supporters 
The clinic staff indicated that all treatment supporters had been educated on the duration of 
TB treatment in courses run over 69 days by the Department of Health. 
3.3.4  Clinic policies 
Staff asked about clinic attendance policies said that all patients were advised to attend their 
clinics/supporters on daily, twice a week or weekly basis depending on the phase of 
treatment. Patients too sick to attend had their medication collected by treatment supporters. 
3.3.5 Problems of patients as stated by clinic staff 
Clinic nurses said that TB patients were faced by social, economic, cultural and clinical 
problems, specifically lack of food, side effects of TB drugs, unemployment, lack of transport, 
having to take time off work. They felt problems could be overcome with home visits, 
observed tablet swallowing, and clinic attendance, a full course of treatment, advice and 
counselling of patients. 
3.3.6  Role of Treatment Supporters 
Nurses said that treatment supporters were responsible for advising and counselling of 
patients, they conducted door to door visits, traced newly diagnosed patients, referred 
patients to clinic, collected pills and gave patients, monitored swallowing of pills, checked on 
treatment interrupters, gave report of treatment support to the clinic, helped weak patients in 
household chores, educated community to bring TB suspects and helped in TB campaigns. 
3.3.7 Improving the role of treatment supporters 
Nurses suggested that supporters needed to be encouraged in meetings, given incentives, 
re-trained, paid promptly on stipends and recognised in the health structure by government.  
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3.3.8  Usefulness of treatment supporters 
All the clinics nurses interviewed said that treatment supporters were very useful to TB 
patients in the community. When asked to state the reason for their answer, they stated that 
the health system relied on treatment supporters’ work since they were strategically 
positioned in the communities where the patients lived. The activities conducted by 
supporters were outlined by clinic nurses as; helping very sick, weak and old patients, 
conducting referrals, giving feedback on home visits, educating community on TB and 
helping in tracing treatment interrupters.  
3.3.9  Meetings between treatment supporters and the clinic staff 
Three clinics had meetings with supporters on a monthly basis and two were meeting once a 
week while one had suspended all the supporter meetings after they demanded for their 
stipends two months ago. 
3.3.10. Suggested other ways in which TB treatment could be improved 
Clinic nurses suggested that patients should be advised to stop drinking alcohol and 
smoking, increase the number of nurses in the clinics, hold TB awareness campaigns in 
hostels and taxi ranks, use technology to remind patients, debrief the staff and treatment 
supporters and educate patients on TB treatment. 
3.4.  Study limitations 
 
A descriptive research design was used in this study. This imposed several limitations that 
could have influenced the data collected and the conclusions reached. These include the 
following;  
• The study assumed that a treatment supporter was present for the entire course of 
treatment. It did not take into account situations whereby a supporter could have been 
absent.  
• Interview data relied on what people said. The reliability of patient interview data 
would have been influenced by their ability to recall their experiences; some patients 
may have had poor memories and may not have given complete and/or accurate 
information. 
• Clinics were chosen from within each Service delivery centre using systematic 
sampling with a random starting point weighting of the clinics within each SDC 
according to TB patient case load, this strategy has potentially biased the samples in 
favour of patient outcomes in the SDCs with smaller caseloads. The ordering of the 
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clinics from which they were selected can dramatically affect the outcomes since only 
two were identified from each SDC. 
4 Discussion 
This section discusses the major findings of the study in three main categories namely, the 
influence of treatment supporters on patients’ treatment outcomes, role of treatment 
supporters, factors associated and not associated with success treatment outcomes.   
4.1 The influence of treatment supporters on patients’ treatment outcomes 
The results showed that there were more successful treatment outcomes in patients who 
had supporters. Further there was stated patients’ satisfaction on the role of treatment 
supporters. This was in line with several other studies. One conducted in South Africa found 
improved outcomes from DOT using lay health workers (25). A randomized controlled trial of 
community health workers versus family members in Swaziland yielded the similar results 
that the treatment supporters could improve treatment outcomes of TB patients (26). A Thai 
study found DOT to be effective while adapting the model of DOT by family members, 
supported by a once weekly home visit from health worker (27).   
It was observed that the treatment success rates (71% for patients with supporters and 51% 
for those without) were lower than the WHO targets of 85% cure for new smear positive 
patients. In addition these were success rates (cure and completed), so were considerably 
below the global target (28).  There is a need to emphasize the use of treatment supporters 
in TB treatment and motivate them so that WHO targets may be reached in future. There 
were 26 patients transferred elsewhere, supporters could have a role in either preventing 
these or in ensuring that transferred patients did attend another clinic.  
It is acknowledged that there could have been factors other than treatment supporters 
presence that could have influenced the treatment outcomes such as extent of TB and drug 
resistance. Although data on these variables were not collected, there is potential influence 
of these factors on treatment outcome. The results may have been influenced sampling 
strategy that had potential bias since the probability of a patient being picked was not equal 
in each of the Service Delivery Centre. 
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4.2 Role of treatment supporters 
Treatment supporters and clinic staff opinions 
A total of 78 (68% of all supported) patients were observed by community supporters while 
37 (32%) patients were observed by clinic nurses. There was no significant association in 
treatment outcomes of the two patient supporters meaning that community supporters were 
as effective as clinic nurses. It does not however address the issue of whether attending 
clinics was as convenient for patients. Treatment supporters stated their role in three 
categories; medication and counselling of patients, practical help and coordination. The clinic 
nurses stated that the health system relied on treatment supporters’ work since they were 
strategically positioned in the communities where the patients lived. The clinic staff are 
considerably assisted by supporters carrying out tasks of conducting door to door visits, 
tracing newly diagnosed patients, checking on treatment interrupters and helping weak 
patients in household chores. 
The role of treatment supporters was found in this study to be far more than just observation 
of treatment but included emotional support and motivation of patients, negotiation with 
families, education of communities and financial/material support of patients. Clinic staff and 
treatment supporters described the role as active finding of TB suspects/ case detection, 
supervision of treatment at the patient household, assisting in collection of medicine, tracing 
of interrupters and conducting home visits. Treatment supporters in Thailand were found to 
be effective in increasing adherence to treatment (27).  
Patients’ opinions 
There was a demonstration of patients’ satisfaction of treatment supporters’ role.  Medication 
and counselling of patients came out as the major role of treatment supporters. They 
assisted the patients with TB to take their medication as prescribed. The supporters watched 
patients take their medication and recorded the dose taken on a card and encouraged them 
on TB treatment. Some patients were supported in medicine collection, washing and food 
preparation.  The supporters provided adequate counselling, easy access to treatment 
especially to the weak patients while receiving ongoing support of the clinic staff. However, 
some patients were dissatisfied mainly because treatment supporters failed to talk to family 
members of patients to change their negative attitudes and these patients also felt that 
supporters were forcing them with medication.  
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4.3 Factors associated and not associated with success treatment outcomes. 
Treatment supporters who had less than 10 patients registered a higher treatment success 
rate 77% as compared to treatment supporters who had more than 10 patients. It is possible 
that these treatment supporters had a manageable number of patients and hence had higher 
success rate than those who had more than ten patients. A recommendation is made for 
further studies to determine the optimum number of patients a treatment supporter should 
have to obtain higher success rate.  
Patients of aged 40 years and above were more likely to have successful treatment 
outcomes than patients of aged less than 40 years. The reason could be that there were 
more supported patients in age 40 years and above than in other age categories who 
achieved treatment success. Treatment support could be emphasized in age groups less 
than 30 years, more than 50 years and in the older category more than 60 years who were 
less likely to achieve treatment success.   
It was found that males were more likely to achieve successful treatment outcomes than 
females. This was evidenced by the number of supported male patients which was higher 
than their female counterparts. There was gender disparity in distribution of treatment 
supporters and this should be corrected in future TB programs.  
Patients living with someone were more likely to achieve treatment success, because it is 
likely the patients were also reminded to take their medication by their partners and to go to 
the clinic. The treatment supporters may have emphasized their support through the 
patient’s partner.  
The proportion of patients with correct knowledge clearly increased with increasing 
education categories. Tertiary and secondary education levels significantly associated with 
patients’ knowledge of treatment duration. Patients who had tertiary and secondary 
education had also significantly achieved successful treatment outcomes. Educational 
exposure may have contributed to comparatively favourable results in this study.  
Knowledge about duration of treatment 
The currently recommended treatment of new pulmonary TB is a drug combination that must 
be taken for six months. Adults with pulmonary tuberculosis are treated with a 6-month 
regimen consisting of daily isoniazid, rifampicin, ethambutol and pyrazinamide for the first 2 
months, followed by isoniazid and rifampicin for 4 months (29).  
There was a significant association between correct knowledge of patients about treatment 
duration and being supported. It is likely that the supporters were educating their patients on 
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duration of treatment. In this study more than 72% of patients and 87% of treatment 
supporters stated six months duration for TB treatment. However, it was surprising 13% of 
treatment supporters did not know the correct duration of treatment of  TB, yet the clinic staff 
stated that all supporters had been educated on the duration of TB treatment in courses run 
over 69 days by the Department of Health. A large proportion (67%) of patients supported by 
these supporters did not give the correct duration of TB. It is important that the clinic staff 
know this and correct it, provide updates and ongoing training for supporters.  
Several studies have been conducted on patients’ knowledge about TB treatment duration. 
According to Peltzer, the patients must possess some minimum level of health knowledge 
and motivation for them to fully understand the treatment regimen, how to take their drugs, 
and the reasons for the long duration of TB treatment (30). Studies in India, Swaziland, 
Thailand and Zambia indicated that poor knowledge about the length of treatment predicts 
interruption behavior and identified that lack of knowledge was a limitation to patients’ 
completion of full course of treatment (31).  
Type of support 
Treatment supporters played an important role in ensuring that medicines collected from 
clinics on behalf of patients were taken as prescribed. This was evidenced by the successful 
outcomes of the patients who had their pills collected by treatment supporters compared to 
those who collected on their own from the clinics, even though the frequency of patients’ 
daily contacts with the clinic staff was higher than with the community treatment supporters. 
Supporters should balance their time for patients who fetch medicine on their own from 
clinics to achieve better outcomes, the study showed that the frequency of patients’ daily 
contacts with the clinic staff was higher than with the community treatment supporters. The 
study revealed that treatment support was not daily for all patients; at the same time the 
clinic staff said that all patients were expected to attend their clinics/treatment supporters 
daily. There is need to emphasise daily support in the program for better treatment 
outcomes. The study found that about two thirds of patients who had interrupted treatment 
did not have treatment supporters. If all patients had treatment supporters treatment 
interruption would be prevented or minimised.  However, treatment outcomes of patients of 
clinic nurses were no better than those of community supporters. This means that 
community supporters were as effective as clinic nurses in treatment support. 
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4.4 Patients stated problems 
Cooperation and relationship between patients and supporters 
There was dialogue between patients and treatment supporters; this was evidenced by 
patients’ ability to discuss their problems with supporters. Some of these discussions 
resulted in patients receiving referral services or attended to by the clinic staff. Some 
patients were dissatisfied with the services rendered by treatment supporters as they 
highlighted unfriendly attitude of supporters while nurses cited poor relationships with 
treatment supporters/health care workers. Peltzer observed that lack of relationship and poor 
communication between patients and treatment supporters could influence patient treatment 
outcomes (30). These findings were in line with Frieden and Driver who examined issues of 
building human bond between patients and health care workers and treatment supporter 
(22). Cooperation of patients was viewed as an important factor in TB treatment, it was also 
the responsibility of the patient to decide everyday or week whether or not to take their 
medicine. In this study some treatment supporters expressed frustration when patient was 
not at home when they went to watch medication, this was because treatment was observed 
largely at patient’s homes. This was in total contrast with the results of Dick et al who found 
that it was the patients who were getting frustrated when the treatment supporter was not at 
home (32). A possible solution to this problem could be when the patient and the supporter 
agreed on a specific place and time to administer the medication as Chadhaetal 
recommends (33).  
Experienced symptoms 
In this study about half of the patients said they experienced symptoms and side effects of 
drugs. This was equally prevalent in those with and without treatment supporters. The 
coordination role of treatment supporters came into play, when they referred such patients to 
clinics for treatment, gave treatment advice and counselled them. 
4.5 Supporters stated problems 
The TB program in some clinics suffered lack of incentives for supporters. Treatment 
supporters expressed a need for stipend increment, more training and extra resources as 
factors that would motivate them. The supporters even went on strike demanding for better 
terms of payment in one clinic. The government policy recognises community based health 
workers as volunteers who are paid stipends. The treatment supporters need to be re- 
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trained in various aspects of DOT support to work effectively. Incentives were observed as 
motivating factors to supporters in their role (11, 12).   
5 Conclusion and recommendations 
5.1 Conclusion 
This study has highlighted the positive role of treatment supporters in influencing successful 
outcomes of treatment of TB patients. To achieve these outcomes, supporters must have 
promoted treatment outcomes. The treatment support seemed to focus on supervision of 
pills intake, tracing patients who had interrupted treatment, collection of medicine and 
treatment counselling. There was a demonstrated patients’ satisfaction about supporters’ 
role as they highlighted frequent visits of supporters, advice on treatment and practical help. 
The supporters gave patients support they required in a manner that was appropriate to their 
emotional and material needs. The treatment outcomes provided proof of usefulness of 
treatment supporters, as supported patients were more likely to have successful treatment 
outcomes than those without supporters.  
 5.2 Recommendations 
 
Increase the number of supporters 
Supporters who had many patients performed worse than those who had less. It is 
recommended that more/all patients should have treatment supporters as only 53% of the 
sample had supporters.  Some supporters were supporting more than ten patients. 
DOT support 
DOT support was not daily as revealed by the study, the results would have been much 
better if supporters did it daily as required. By definition DOT is daily observed treatment. 
There is need to encourage treatment supporters to provide daily support. 
Support for TB clinic staff and treatment supporters  
The clinic staff proposed encouragements and debriefing sessions for treatment supporters 
and TB staff. It is recommended that the TB program should also ensure that treatment 
supporters and the TB nurses receive the necessary incentives, recognition and psycho -
social support since the work entailed handling patients in critical conditions including dying 
patients. They even sometimes attend funerals. This will help in addressing the burn out 
effect that usually results in caregivers, treatment supporters and counselors. 
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Dissemination of report 
 
This report will be disseminated to The University of the Witwatersrand, Ekurhuleni 
Metropolitan Municipality, and submitted for publication with the help of my supervisor. 
Findings will be shared with the School of Public Health, Ekurhuleni Metropolitan Municipality 
district health management and staff, research participants including clinic staff and 
coordinators. The findings will also be presented to Gauteng Health Department policy 
makers and to communities including the treatment supporters and patients. 
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APPENDIX 1 
Fixed Sample in selected clinics 
 
Service 
Delivery 
Centre 
Clinics No of adult TB patients 
registered in April and May 
2006 
No of community 
treatment supporters 
attached to clinic 
Germiston 
S1 
Germiston 
clinic 
25 5 
 Moleleki  49 8 
Alberton 
S2 
Phola park 
clinic 
32 4 
 Phenduka 28 5 
Boksburg 
S3 
Vosloorus 
Poly Clinic 
46 4 
 Reiger Park 
Clinic 
42 4 
Total  222 30 
Note: These are new TB treatment patients 
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APPENDIX 2 
QUESTIONNAIRE I 
  TB TREATMENT     
         
 PATIENTS INTERVIEW QUESTIONS    
         
   
SECTION A 
DEMOGRAPHICS     
         
1.  Study number: PS      PNS     
         
2. Sex:    Male    Female   
         
3. Age (in years):            
         
4. Marital Status     Single    
      Married    
      Live with partner   
      Divorced    
      Separated   
      Other     
5. Educational level:  Highest Grade       
         
6. Name of clinic attending:         
         
7. Date of registration in clinic (check in patient card):       
         
8. Do you have a person who helps/supports you in TB treatment?  
     Yes   No   
         
9. What mode of transport do you use to get to the clinic?  
       Walk   
       Taxi   
       Train   
       Bicycle   
       Own car   
       
Family 
car   
       Beg a lift   
       Other   
         
10. For how long should you take TB treatment?     
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11. How do you get your treatment?       
11.a) I go to clinic to fetch my pills  Daily    
      3 times a week   
      2 times a week   
      Weekly    
      every 2 weeks   
      every month   
      other      
11. b) Treatment supporter collects my pills from clinic & brings to me at home 
      Daily    
      3 times a week   
      2 times a week   
      Weekly    
      every 2 weeks   
      every month   
      other      
         
11.c) Treatment supporter collects my pills from clinic and I go fetch from her 
         
      Daily    
      3 times a week   
      2 times a week   
      Weekly    
      every 2 weeks   
      every month   
      other      
         
12. How do you take your pills?      
     No one watches    
     Clinic nurse watches   
     
Treatment supporter 
watches   
     
Sometimes someone 
watches   
     
Someone watches (say 
who)   
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13. What are the problems you are facing in TB treatment? 
    Taking time off work    
    Being unemployed     
    Family attitude bad     
    Community attitude bad    
    I feel sick     
    Side effects of drugs    
    No one to collect medicine for me   
    Transport to clinic     
     lack of food     
    Clinic staff attitude     
    Other (specify)      
 Write responses here      
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    SECTION B    
         
  PATIENTS WITH TREATMENT SUPPORTERS 
         
14. What is your relationship with the supporter?  Neighbor   
      colleague    
      family member   
      no relationship   
      Church member   
      Other     
         
15. Do treatment supporters ever accompany you to the clinic to fetch pills? 
         
    Yes    No   
         
16. What does the treatment supporter do for you?    
    Ask about my progress    
    Give medicine     
    Remind me on clinic days    
    check if took medicine as prescribed   
    Counsel and advise me on medication   
    Others (specify)         
             
         
17. Do you ever go to treatment supporter's home to seek for help?  
     Yes   No   
         
 If yes, how often do you go to treatment supporter's home for help? 
      Daily    
      every 2nd day   
      every 3rd day   
      every 4th day   
      every 5th day   
      Once a week   
      once in 2 weeks   
      once in 3 weeks   
      once in 4 weeks   
      Other (specify)   
 Write responses here      
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18. Do you find your community treatment supporter helpful? 
     Yes   No   
         
 
If yes, Explain 
why             
                 
 If No, state why              
                 
         
         
19. What do you think your treatment supporter could do to help with any problems 
You have?       
   Bring medicine to me     
   Convenient for me to fetch medicine from him/her   
   Talk/counsel/encourage me     
   Give me food      
   Tell me when to go to the clinic    
   Talk to my family      
   I don’t know      
   Other (specify)              
         
 Write responses here      
                 
                 
         
                 
                 
                 
         
         
PS=Patient with supporter       
PNS=Patient without 
supporter        
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QUESTIONNAIRE II 
 
  TB TREATMENT    
FORM 
CPS 
         
 TREATMENT SUPPORTERS    
         
DEMOGRAPHICS       
          
1. Study 
number:      CPS   
         
2. Sex:    Male    Female   
         
3. Age (in 
years):          
         
4. Marital Status     Single    
      Married    
      Live with partner   
      Divorced    
      Separated   
      Other     
         
5. Educational 
level:  Highest Grade      
         
6. Name of clinic attached 
to:        
         
7. Number of patients under your care:       
         
8. a. Where do you see your TB patients for treatment supporters?  
      Clinic    
      their homes   
      my home   
      Work    
      Other     
         
    b. How do you support your patients?     
I go to the clinic with them to fetch medicine      
I go to the clinic myself to collect medicine and take to patients in their 
homes   
I go to the clinic myself to collect medicine then patients comes to me   
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    c. For selected category in 8a, How often do you see them?   
      Daily    
      every 2nd day   
      every 3rd day   
      every 4th day   
      every 5th day   
      Once a week   
      once in 2 weeks   
      once in 3 weeks   
      once in 4 weeks   
      Other (specify)   
         
   d. If you visit patients at home, how long does it take you to do the support 
job? 
           
         
 Is the home visit time the same for all your TB patients?  
     Yes   No   
         
9. What do you do for the patients you are supporting?   
   Watch them take medication     
   Encourage them      
   write/tick on card when medicine taken    
   educate/talk/counsel them about taking TB medicine   
   Take food      
   other        
         
10. What problems do patients tell you about, relating to the TB treatment? 
    Taking time off work    
    Being unemployed     
    Family attitude bad     
    Community attitude bad    
    I feel sick     
    Side effects of drugs    
    No one to collect medicine for me   
    Transport to clinic     
    lack of food     
    Clinic staff attitude     
    Other (specify)      
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11. What are the problems you are facing in assisting your patients in TB 
treatment? 
    patient not at home when I visit   
    patients do not attend at my home   
    patient complain of side effects   
    patient complain of no food    
    It takes time for me to visit patients   
    Other (specify)      
12. What do you do to overcome these difficulties?    
    Monitoring of medication    
    Collection of medicine    
    Transport     
    Provision of food     
    Tell clinic staff to treat side effects   
    Don’t know     
    Other (specify)           
         
13. How long should patients take TB treatment? (in months)     
         
14. Do you have meetings with TB clinic staff?    Yes   No   
         
      If yes, How often do you meet with TB clinic staffs staff?      Weekly   
      every 2 week   
      Monthly    
      every 2 month   
      Never    
      other (specify)   
15. What do you suggest can improve role of treatment supporters? 
       Yes No 
    Increase pay      
    Appreciation from clinic staff     
    More training      
    Provide transport to clinic     
    Extra resources e.g. kits     
    Other (specify)      
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QUESTIONNAIRE III 
 KEY INFORMANT INTERVIEWS WITH TB CLINIC STAFF  
         
1. Study No.           
         
2. Name of clinic:         
         
3. Position in clinic:        
         
4. Do you have treatment supporters attached to this clinic?  
         
     Yes   No   
         
5. How many treatment supporters are there?      
         
6. What do the treatment supporters do? List and Explain   
                 
                 
         
7. How often do you meet with treatment supporters in the clinic?  
      Daily    
      Weekly    
      Every 2 weeks   
      Every 3 weeks   
      Monthly    
      Never    
      Other     
          
8. Did the treatment supporters complete the 69 days course?   
     Yes   No   
9. How many treatment supporters are supporting more than seven patients? 
          
10. Patients may have problems in taking treatment, what problems do 
patients tell you about relating to TB treatment? List them 
                 
                 
11. What do you do to help the treatment 
supporters?    
    Train  more treatment supporters   
    debriefing sessions     
    Meeting with them     
    Give incentives     
    Retrain treatment supporters   
    Others       
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12. What do you do to help the TB patients in treatment?   
    Advise and counsel patients about TB   
    Encourage supervised swallowing   
    Encourage them to come to clinic regularly   
    Encourage home visits    
    Encourage taking full course treatment   
    Others       
         
13. Do you think treatment supporters are useful in assisting TB patients? 
     Yes   No   
         
 
If useful, explain 
why?           
                 
         
 
If not useful, 
explain why?           
                 
         
14. What would improve the role of treatment 
supporters?    
                 
                 
                 
                 
         
15. Are there ways apart from supporters in which TB treatment adherence 
could be improved? 
                             
                 
                 
                 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50  
APPENDIX 3 
 
PATIENT INFORMATION LEAFLET 
 
Hi my name is __________; I am one of a team of four interviewers involved in a study being 
conducted for a course at the University of Witwatersrand. We want to study people who are 
taking TB treatment and ask them some questions about how they are getting their 
treatment. We are interested to know if Treatment supporters are helpful.  
 
I would like to ask for your participation in a ten minutes interview on the role of Treatment 
supporters in TB treatment if you do not mind.  
 
We do have permission from Human Research Ethics Committees of University of 
Witwatersrand and Ekurhuleni Metropolitan Municipality allowing us to conduct this research.  
 
You were randomly chosen from TB patients on treatment in clinics in Ekurhuleni 
Metropolitan Municipality. 
 
Participation in this study is voluntary and you are free to refuse to participate or to withdraw 
your consent and to discontinue participation at any time. Such refusal or discontinuance will 
not affect your regular treatments or Medical care in any way. Also, you do not have to 
answer all questions; you may answer some questions but not all. If you refuse to answer 
questions, it will not affect your TB treatment at all. If you agree to participate in this study, 
would you please sign the consent form? 
 
We will not disclose your name or connect your name with anything you say. 
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INFORMED CONSENT OF PATIENTS 
 
I have been fully informed about the study, which will ask me questions about my TB 
treatment. I have also received, read and understood the above written information 
(Participant Information Leaflet and Informed Consent) regarding the study. 
 
I am aware that the results of the study will be anonymously processed into a study report, 
and my name will not appear in any report.  
 
In signing this consent form, I agree to the questions and I understand that I am free to 
refuse to participate or to withdraw my consent.  
 
 
PARTICIPANT: 
 
 
 
 
Printed Name Signature / Mark or Thumbprint  Date and Time 
 
 
WITNESS: 
 
 
 
Printed Name Signature      Date and Time 
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CLINICS TB STAFF INFORMATION LEAFLET 
 
Hi my name is ___________; I am one of a team of four interviewers involved in a study 
being conducted for a course at the University of Witwatersrand. We want to study if the 
Treatment supporters influence TB patients’ treatment outcomes and would like to ask your 
opinion about how they assist patients in their treatment.  
 
I would like to ask for your participation in a ten minutes interview on the role of Treatment 
supporters in TB treatment if you do not mind.  
 
We do have permission from Human Research Ethics Committees of University of 
Witwatersrand and Ekurhuleni Metropolitan Municipality allowing us to conduct this research.  
 
You were randomly chosen from clinics TB staff in Ekurhuleni Metropolitan Municipality. 
 
Participation in this study is voluntary and you are free to refuse to participate or to withdraw 
your consent and to discontinue participation at any time. Such refusal or discontinuance will 
not affect your regular treatments or Medical care in any way. Also, you do not have to 
answer all questions; you may answer some questions but not all. If you refuse to answer 
questions, it will not affect your TB treatment at all. If you agree to participate in this study, 
would you please sign the consent form? 
 
We will not disclose your name or connect your name with anything you say. 
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INFORMED CONSENT OF CLINIC STAFF MEMBERS 
 
I have been fully informed about the study which will ask me questions about the role of 
treatment supporters in influencing TB treatment outcomes. I have also received, read and 
understood the above written information (Participant Information Leaflet and Informed 
Consent) regarding the study. 
 
I am aware that the results of the study will be anonymously processed into a study report, 
and my name will not appear in any report.  
 
In signing this consent form, I agree to the questions and I understand that I am free to 
refuse to participate or to withdraw my consent.  
 
 
PARTICIPANT: 
 
 
 
 
Printed Name Signature / Mark or Thumbprint  Date and Time 
 
 
WITNESS: 
 
 
 
Printed Name Signature      Date and Time 
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TREATMENT SUPPORTERS INFORMATION LEAFLET 
 
Hi my name is __________; I am one of a team of four interviewers involved in a study being 
conducted for a course at the University of Witwatersrand. We want to study if the treatment 
supporters influence TB patients’ treatment outcomes and ask them some questions about 
how they are assisting patients in their treatment.  
 
I would like to ask for your participation in a ten minutes interview on the role of Treatment 
supporters in TB treatment adherence if you do not mind.  
 
We do have permission from Human Research Ethics Committees of University of 
Witwatersrand and Ekurhuleni Metropolitan Municipality allowing us to conduct this research.  
 
You were randomly chosen from Treatment supporters in clinics in Ekurhuleni Metropolitan 
Municipality. 
 
Participation in this study is voluntary and you are free to refuse to participate or to withdraw 
your consent and to discontinue participation at any time. Such refusal or discontinuance will 
not affect your regular treatments or Medical care in any way. Also, you do not have to 
answer all questions; you may answer some questions but not all. If you refuse to answer 
questions, it will not affect your TB treatment at all. If you agree to participate in this study, 
would you please sign the consent form? 
 
We will not disclose your name or connect your name with anything you say. 
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INFORMED CONSENT OF TREATMENT SUPPORTERS 
 
I have been fully informed about the study which will ask me questions about my role as a 
treatment supporter of TB patients. I have also received, read and understood the above 
written information (Participant Information Leaflet and Informed Consent) regarding the 
study. 
 
I am aware that the results of the study will be anonymously processed into a study report, 
and my name will not appear in any report.  
 
In signing this consent form, I agree to the questions and I understand that I am free to 
refuse to participate or to withdraw my consent.  
 
 
PARTICIPANT: 
 
 
 
 
Printed Name  Signature / Mark or Thumbprint  Date and Time 
 
 
WITNESS: 
 
 
 
Printed Name Signature      Date and Time 
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